Trials of Immunotherapy in Triple Negative Breast Cancer

被引：1

作者：

Gumusay, Ozge ^{[1
]}

Wabl, Chiara A. ^{[1
]}

Rugo, Hope S. ^{[1
]}

机构：

[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

来源：

CURRENT BREAST CANCER REPORTS | 2021年 / 13卷 / 03期

关键词：

Triple negative breast cancer; Immune checkpoint inhibitors; Immunotherapy; Atezolizumab; Pembrolizumab; PEMBROLIZUMAB PLUS CHEMOTHERAPY; TUMOR-INFILTRATING LYMPHOCYTES; DOUBLE-BLIND; ANTI-PD-L1; ANTIBODY; PD-L1; EXPRESSION; PHASE-III; PROGNOSTIC VALUE; OPEN-LABEL; HIGH-RISK; PACLITAXEL;

D O I：

10.1007/s12609-021-00418-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of Review Triple negative breast cancer (TNBC) is an aggressive subtype with frequent chemotherapy resistance. In recent years, advances in immunotherapy have yielded promising new therapeutic strategies for the treatment of TNBC; studies evaluating immune check point inhibitors (ICIs) in combination with chemotherapy have shown encouraging results in both early and advanced stages of disease. Recent Findings Atezolizumab plus nab-paclitaxel resulted in improved progression-free survival (PFS) and overall survival (OS) compared to nab-paclitaxel alone in patients with programmed death-ligand 1-positive (PD-L1+) metastatic TNBC (mTNBC). However, atezolizumab plus paclitaxel did not improve outcomes. Pembrolizumab plus chemotherapy improved PFS compared to chemotherapy alone in patients with PD-L1+ mTNBC, and follow-up for OS is ongoing. The addition of pembrolizumab and atezolizumab to neoadjuvant chemotherapy increased pathologic complete response rates, regardless of PD-L1 status, and event-free survival is pending. Several other combinations of ICIs with targeted agents are under investigation to enhance the host immune response and are discussed in this review. TNBC has a poor prognosis with limited treatment options. Recent studies have demonstrated encouraging results by adding ICIs to chemotherapy, although optimal combinations remain to be defined. In this review, we highlight advances in TNBC treatment including ICIs and targeted agents and also discuss future directions.

引用

页码：171 / 185

页数：15

共 92 条

[21] Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer [J].

Denkert, Carsten ;

Loibl, Sibylle ;

Noske, Aurelia ;

Roller, Marc ;

Mueller, Berit Maria ;

Komor, Martina ;

Budczies, Jan ;

Darb-Esfahani, Silvia ;

Kronenwett, Ralf ;

Hanusch, Claus ;

von Toerne, Christian ;

Weichert, Wilko ;

Engels, Knut ;

Solbach, Christine ;

Schrader, Iris ;

Dietel, Manfred ;

von Minckwitz, Gunter .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :105-113

[22]

Dent R KS, 2020, 2020 SAN ANT BREAST

[23] Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study [J].

Dirix, Luc Y. ;

Takacs, Istvan ;

Jerusalem, Guy ;

Nikolinakos, Petros ;

Arkenau, Hendrik-Tobias ;

Forero-Torres, Andres ;

Boccia, Ralph ;

Lippman, Marc E. ;

Somer, Robert ;

Smakal, Martin ;

Emens, Leisha A. ;

Hrinczenko, Borys ;

Edenfield, William ;

Gurtler, Jayne ;

von Heydebreck, Anja ;

Grote, Hans Juergen ;

Chin, Kevin ;

Hamilton, Erika P. .

BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (03) :671-686

[24]

Domchek S, 2019, ANN ONCOL, V30, P477

[25]

Domchek SM., 2018, NTR

[26] Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study [J].

Domchek, Susan M. ;

Postel-Vinay, Sophie ;

Im, Seock-Ah ;

Park, Yeon Hee ;

Delord, Jean-Pierre ;

Italiano, Antoine ;

Alexandre, Jerome ;

You, Benoit ;

Bastian, Sara ;

Krebs, Matthew G. ;

Wang, Ding ;

Waqar, Saiama N. ;

Lanasa, Mark ;

Rhee, Joon ;

Gao, Haiyan ;

Rocher-Ros, Vidalba ;

Jones, Emma, V ;

Gulati, Sakshi ;

Coenen-Stass, Anna ;

Kozarewa, Iwanka ;

Lai, Zhongwu ;

Angell, Helen K. ;

Opincar, Laura ;

Herbolsheimer, Pia ;

Kaufman, Bella .

LANCET ONCOLOGY, 2020, 21 (09) :1155-1164

[27] IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer [J].

Emens, L. A. ;

Adams, S. ;

Barrios, C. H. ;

Dieras, V. C. ;

Iwata, H. ;

Loi, S. ;

Rugo, H. S. ;

Schneeweiss, A. ;

Winer, E. P. ;

Patel, S. ;

Henschel, V. ;

Swat, A. ;

Kaul, M. ;

Molinero, L. ;

Chui, S. Y. ;

Schmid, P. .

ANNALS OF ONCOLOGY, 2020, 31 :S1148-S1148

[28] Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study [J].

Emens, Leisha A. ;

Cruz, Cristina ;

Eder, Joseph Paul ;

Braiteh, Fadi ;

Chung, Cathie ;

Tolaney, Sara M. ;

Kuter, Irene ;

Nanda, Rita ;

Cassier, Philippe A. ;

Delord, Jean-Pierre ;

Gordon, Michael S. ;

ElGabry, Ehab ;

Chang, Ching-Wei ;

Sarkar, Indrani ;

Grossman, William ;

O'Hear, Carol ;

Fasso, Marcella ;

Molinero, Luciana ;

Schmid, Peter .

JAMA ONCOLOGY, 2019, 5 (01) :74-82

[29] The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors [J].

Ghebeh, Hazem ;

Mohammed, Shamayel ;

Al-Omair, Abeer ;

Qattan, Amal ;

Lehe, Cynthia ;

Al-Qudaihi, Ghofran ;

Elkum, Naser ;

Alshabanah, Mohamed ;

Bin Amer, Suad ;

Tulbah, Asma ;

Ajarim, Dahish ;

Al-Tweigeri, Taher ;

Dermime, Said .

NEOPLASIA, 2006, 8 (03) :190-198

[30] Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study [J].

Gianni, Luca ;

Huang, Chiun-Sheng ;

Egle, Daniel ;

Bermejo, Begona ;

Zamagni, Claudio ;

Thill, Marc ;

Anton, Antonio ;

Zambelli, Stefania ;

Bianchini, Giampaolo ;

Russo, Stefania ;

Ciruelos, Eva ;

Greil, Richrad ;

Semiglazov, Vladimir ;

Colleoni, Marco ;

Kelly, Catherine ;

Mariani, Gabriella ;

Del Mastro, Lucia ;

Maffeis, Ilaria ;

Valagussa, Pinuccia ;

Viale, Giuseppe .

CANCER RESEARCH, 2020, 80 (04)

← 1 2 3 4 5 6 7 8 9 10 →